Join Here   |   Log In

Hypophosphatasia (HPP) and the ALPL Gene

Key takeaways:

  • Hypophosphatasia is caused by mutations in the ALPL gene, which reduce the activity of tissue‑nonspecific alkaline phosphatase (TNAP), an enzyme that’s important for bone, tooth, liver, and kidney health.
  • Low ALP allows pyrophosphate and active vitamin B6 (P5P) to build up, interfering with normal bone mineralization.
  • Single ALPL mutations can be associated with low‑normal ALP and higher rates of bone and dental issues, and may underlie osteoporosis in a subset of patients.
  • Adult-onset HPP symptoms can mimic fibromyalgia.
Members will see their genotype report below and the solutions in the Lifehacks section. Consider joining today

What is hypophosphatasia, and how is it related to low ALP?

Hypophosphatasia (HPP) is an inherited disorder involving low alkaline phosphatase. It’s caused by mutations in the ALPL gene. There is both a severe form that affects infants and children and a milder, adult-onset form.

The ALPL gene encodes the tissue-nonspecific isoenzyme of alkaline phosphatase, abbreviated TNAP.

Alkaline phosphatase (ALP) may sound familiar as a marker that is common on standard blood tests. Doctors look at it as a marker of liver health. It’s an enzyme that removes phosphate groups from other molecules in the body. The enzyme contains zinc and magnesium, making these minerals essential for its activity. It also incorporates the active form of vitamin B6, called pyridoxal 5′-phosphate (P5P).

There are multiple ALPs, and the ALPL gene codes for a specific type of alkaline phosphatase called tissue-nonspecific (TNAP). It is found most abundantly in the liver, bone, and kidneys, but is also at low levels throughout the body. In the bone, it is important for remineralization and the incorporation of phosphorus into bones. [ref]

What constitutes low ALP? The standard range for adults is 40 to 130 U/L for males and 35 to 104 U/L for females. Below 35 (females) or 40 (males) U/L is considered low or abnormal on most test ranges.  [ref]

Hypophosphatasia: ALPL mutations and low ALP levels

Hypophosphatasia is caused by a lack of tissue non-specific ALP (TNAP).

A lack of ALP allows for the buildup of its substrates – inorganic phosphate (pyrophosphate) and pyridoxal 5′-phosphate (active vitamin B6).  An excess of pyrophosphate can inhibit how bones and teeth use phosphorus and calcium for remineralization.[ref]

There are two forms of hypophosphatasia:[ref]

  • Childhood onset: more severe forms cause significant problems with bone growth, teeth formation, and even seizures
  • Adult-onset: milder form that is associated with low bone mineral density, bone pain, muscle weakness, and dental problems.

Essentially, the problem from low ALP activity is that it leads to the accumulation of inorganic pyrophosphate (PPi), which feeds back to inhibit bone mineralization, and pyridoxal 5′-phosphate. Urinary phosphoethanolamine (PEA) is usually elevated.[ref][ref]

Why high serum B6 levels?
Tissue non-specific ALP (TNAP) normally acts on the active form of vitamin B6, pyridoxal 5′-phosphate, by removing a phosphate group so that it can cross cell membranes. Without enough ALP, the pyridoxal 5’phosphate (P5P) accumulates outside the cells, causing high serum vitamin B6 levels. Cellular levels may still remain normal in some people. One way that doctors can detect HPP is to do a vitamin B6 challenge – giving patients 20mg the regular form of B6 (pyridoxine hydrochloride) for 2 days to see if their serum P5P (active B6) elevates significantly.[ref][ref]

Children with HPP:

Children born with two copies of rare, pathogenic ALPL mutations can develop problems with bone health (rickets) and tooth development from a very early age. An excess of vitamin B6 can also have detrimental effects, including seizures or neurological effects. This is a condition that is usually apparent and diagnosed in early childhood.[ref]

Adult-onset form of HPP: Symptoms and health issues

The severe and significant problems with bone health are easy to see and understand in children with HPP. The adult-onset form is more nuanced.

To be clear, the term ‘adult-onset’ is a bit of a misnomer, in my opinion. This is a condition that develops over years of low ALP and higher levels of inorganic pyrophosphate and P5P, so it is more the case that the changes aren’t fully noticed until adulthood.

In adults, skeletal symptoms can include:[ref][ref][ref]

  • osteoporosis
  • abnormal teeth or loose teeth
  • stress fractures
  • bone or muscle pain (often misdiagnosed as fibromyalgia)
  • pain and stiffness in back or legs
  • muscle weakness
  • calcific periarthritis – calcium hydroxyapatite crystal deposits in the soft tissues around a joint

Hypophosphatasia is more than just ‘soft bones’, though.

Non-skeletal symptoms include:[ref]

  • kidney problems
  • hearing loss
  • depression/anxiety
  • headaches
  • fatigue, generalized pain

Carriers of a single ALPL mutation:

While childhood-onset hypophosphatasia is generally caused by two ALPL mutations, carrying just one mutation often causes few or no readily noticeable symptoms.

However, recent advances in whole-genome sequencing and large genetic databases show that carrying a rare mutation may have some effects.

Researchers used the Vanderbilt University DNA Biobank database to find individuals with hypophosphatasia mutations. They found that out of 25,000+ people in the database, 105 had ALPL mutations. These individuals had low-normal or below-normal ALP levels. Of those identified, about 40% of the men and 62% of the women had documented bone or dental diseases in their health records. In addition, 40% of the women had ovarian or gynecological abnormalities.[ref]

Osteoporosis and ALPL mutations:

People with ALPL mutations may be at a higher risk of osteoporosis. A large study at an osteoporosis center found that 0.5% of the patients had low ALP levels, and most of the low ALP patients also carried single copies of pathogenic ALPL gene mutations.[ref]

While there are many causes of osteoporosis, for some, ALPL mutations may be an uncommon root cause.

Related article: Osteoporosis genes

Fibromyalgia misdiagnosis possible:

The symptoms of adult-onset hypophosphatasia are similar in many ways to fibromyalgia. A study of ~ 600 fibromyalgia patients found that almost 10% had consistently low ALP levels that could indicate HPP, although none had genetic testing or vitamin B6 test results.[ref]

Related article: Fibromyalgia genes

What else – other than an ALPL mutation – can cause low ALP levels?

ALP levels can also be low, usually transiently, due to specific conditions:[ref][ref][ref]

  • lung or respiratory infections with Francisella tularensis bacteria cause low ALP levels
  • cancer or severe illness
  • low magnesium or B6 deficiency
  • excess vitamin D
  • Celiac disease, malnutrition (check your genes)
  • hypoparathyroidism
  • Wilson’s disease (check your genes)
  • lab errors

Genotype report: ALPL and HPP

ALPL gene: encodes an enzyme called tissue-nonspecific alkaline phosphatase (TNSALP), which acts as a phosphatase, which means that it removes phosphate groups from other molecules.

Access this content:

An active subscription is required to access this content.

Join as a member


 


Lifehacks:

Think you have adult-onset hypophosphatasia? Talk with your doctor

If you have persistently low ALP levels, talk with your doctor about whether adult hypophosphatasia is a possible diagnosis. Additional tests, such as B6 or urinary PEA levels, may be needed for a definitive diagnosis, along with genetic testing. [ref][ref]

Why is diagnosis important? [ref]

  • There is a prescription-only replacement enzyme called Asfotase alfa enzyme replacement therapy (ERT) available.
  • In addition, certain medications, such as Bisphosphonates, denosumab, and excess vitamin D, may need to be avoided.

Need to find a doctor or specialist? Soft Bones may be able to help: https://softbones.org/newly-diagnosed/

In addition, talk with your doctor before taking any supplements. While I couldn’t find any information directly related to supplementing with PEA (phosphoethanolamine), it seems like it might be counterindicated with HPP.

Ways to support low ALP levels:

Zinc:
Zinc is a cofactor for tissue non-specific ALP. A deficiency of zinc can exacerbate low ALP levels, so ensuring that you get enough zinc is important with ALP variants.[ref] A case series in adults with hypophosphatasia who were overlooked for a long time showed that zinc supplements were helpful in mitigating the milder symptoms of HPP.[ref]

Magnesium:
Similar to zinc, magnesium is a structural cofactor in ALP. Magnesium deficiency can cause lower ALP levels, even without genetic ALPL variants. If you have HPP, consider testing your magnesium levels and making sure you are getting plenty in your diet.[ref]

Vitamin B6? In adults with HPP, vitamin B6 insufficiency can occur. However, there are a lot of questions about the type and dosage, so this type of supplementation is best done with a doctor’s help and specific testing.[ref]

Drinking water source: 

Higher ALP levels are found in children drinking reverse osmosis water compared to non-reverse osmosis sources.  Serum phosphorus levels were lower in RO water drinkers than in non-reverse osmosis water drinkers.[ref]


Related articles:

Ehlers Danlos Syndrome: Genes, Types, and Treatments

Osteoporosis: Genetic Susceptibility and Prevention Strategies

Fibromyalgia: Underlying Causes and Genetic Connections


References:

Alonso, Nerea, et al. “Loss‐of‐Function Mutations in the ALPL Gene Presenting with Adult Onset Osteoporosis and Low Serum Concentrations of Total Alkaline Phosphatase.” Journal of Bone and Mineral Research, vol. 35, no. 4, Apr. 2020, pp. 657–61. PubMed Central, https://doi.org/10.1002/jbmr.3928.
Alvarez, Sofía, et al. “Vitamin B6 Challenge as a Tool for Detecting ALPL Mutations and Diagnosing Hypophosphatasia.” Osteoporosis International, vol. 36, no. 9, 2025, pp. 1743–47. PubMed Central, https://doi.org/10.1007/s00198-025-07595-x.
Arulanandam, Bernard P., et al. “Francisella DnaK Inhibits Tissue-Nonspecific Alkaline Phosphatase.” The Journal of Biological Chemistry, vol. 287, no. 44, Oct. 2012, pp. 37185–94. PubMed Central, https://doi.org/10.1074/jbc.M112.404400.
d’Angelo, Debora Mariarita, et al. “Safety and Efficacy of Long Term Asfotase Alfa Treatment in Childhood Hypophosphatasia.” Italian Journal of Pediatrics, vol. 51, Mar. 2025, p. 86. PubMed Central, https://doi.org/10.1186/s13052-025-01883-2.
Dahir, Kathryn M., et al. “Rare Variants in the Gene ALPL That Cause Hypophosphatasia Are Strongly Associated With Ovarian and Uterine Disorders.” The Journal of Clinical Endocrinology and Metabolism, vol. 103, no. 6, Apr. 2018, pp. 2234–43. PubMed Central, https://doi.org/10.1210/jc.2017-02676.
Dahir, Kathryn M., and Mark E. Nunes. “Hypophosphatasia.” GeneReviews®, edited by Margaret P. Adam et al., University of Washington, Seattle, 1993. PubMed, http://www.ncbi.nlm.nih.gov/books/NBK1150/.
Hoff, Paula, et al. “Clinical Presentation of Adults with Persistently Low Alkaline Phosphatase Activity: A Retrospective Multicentre, Cross-Sectional Study in Germany.” BMJ Open, vol. 15, no. 7, July 2025, p. e097235. PubMed Central, https://doi.org/10.1136/bmjopen-2024-097235.
Injean, Patil, et al. “Could Some Patients With Fibromyalgia Potentially Have Hypophosphatasia? A Retrospective Single-Center Study.” ACR Open Rheumatology, vol. 5, no. 10, Oct. 2023, pp. 524–28. PubMed, https://doi.org/10.1002/acr2.11591.
Inoue, Daisuke. “Diagnosis and Treatment of Adult Hypophosphatasia: Still a Big Challenge?” Osteoporosis and Sarcopenia, vol. 10, no. 1, Mar. 2024, pp. 1–2. PubMed Central, https://doi.org/10.1016/j.afos.2024.03.002.
Kawashima, Hisashi, et al. “Case Series Demonstrating the Effectiveness of Zn Supplements in Adults with Hypophosphatasia Who Were Overlooked for a Long Time.” SAGE Open Medical Case Reports, vol. 13, July 2025, p. 2050313X251360163. PubMed Central, https://doi.org/10.1177/2050313X251360163.
Khan, Aliya A., et al. “Hypophosphatasia Diagnosis: Current State of the Art and Proposed Diagnostic Criteria for Children and Adults.” Osteoporosis International, vol. 35, no. 3, Mar. 2024, pp. 431–38. Springer Link, https://doi.org/10.1007/s00198-023-06844-1.
Kishnani, Priya S., et al. “Revisiting the Genetics of Hypophosphatasia.” Journal of Inherited Metabolic Disease, vol. 48, no. 6, Nov. 2025, p. e70083. PubMed Central, https://doi.org/10.1002/jimd.70083.
Matsuda, Nozomi, et al. “Potential Pathological Role of Single Nucleotide Polymorphism (c.787T>C) in Alkaline Phosphatase (ALPL) for the Phenotypes of Hypophosphatasia.” Endocrine Journal, vol. 67, no. 12, Dec. 2020, pp. 1227–32. PubMed, https://doi.org/10.1507/endocrj.EJ20-0203.
Millán, Jose Luis. “Hypophosphatasia—Pathophysiological Understanding, Preclinical Data Looking beyond the Skeleton, and Upcoming Treatments.” Journal of Bone and Mineral Research, vol. 41, no. 3, Oct. 2025, pp. 208–19. PubMed Central, https://doi.org/10.1093/jbmr/zjaf141.
NM_000478.6(ALPL):C.571G>A (p.Glu191Lys) AND Inborn Genetic Diseases – ClinVar – NCBI. https://www.ncbi.nlm.nih.gov/clinvar/RCV002513051/. Accessed 29 July 2026.
Riancho, Jose A. “Diagnostic Approach to Patients with Low Serum Alkaline Phosphatase.” Calcified Tissue International, vol. 112, no. 3, Mar. 2023, pp. 289–96. PubMed, https://doi.org/10.1007/s00223-022-01039-y.
Rs3200254 RefSNP Report – dbSNP – NCBI. https://www.ncbi.nlm.nih.gov/snp/rs3200254. Accessed 29 July 2026.
Rs121918000 RefSNP Report – dbSNP – NCBI. https://www.ncbi.nlm.nih.gov/snp/rs121918000. Accessed 29 July 2026.
Rs121918002 RefSNP Report – dbSNP – NCBI. https://www.ncbi.nlm.nih.gov/snp/rs121918002. Accessed 29 July 2026.
Rs121918010 RefSNP Report – dbSNP – NCBI. https://www.ncbi.nlm.nih.gov/snp/rs121918010. Accessed 29 July 2026.
Rs121918011 RefSNP Report – dbSNP – NCBI. https://www.ncbi.nlm.nih.gov/snp/rs121918011. Accessed 29 July 2026.
Rs121918020 RefSNP Report – dbSNP – NCBI. https://www.ncbi.nlm.nih.gov/snp/rs121918020. Accessed 29 July 2026.
Rs199590449 RefSNP Report – dbSNP – NCBI. https://www.ncbi.nlm.nih.gov/snp/rs199590449. Accessed 29 July 2026.
Sharma, Ujjawal, et al. “Alkaline Phosphatase: An Overview.” Indian Journal of Clinical Biochemistry, vol. 29, no. 3, July 2014, pp. 269–78. PubMed Central, https://doi.org/10.1007/s12291-013-0408-y.
Thippeswamy , H. M., et al. “Comparison of Serum Calcium, Magnesium, Phosphate, Alkaline Phosphatase, and Vitamin D Levels in Children Consuming Reverse Osmosis, Non Reverse Osmosis, and High Fluoride Drinking Water.” Scientific Reports, vol. 15, no. 1, Mar. 2025, p. 10689. www.nature.com, https://doi.org/10.1038/s41598-025-94758-9.
Tournis, Symeon, et al. “Hypophosphatasia.” Journal of Clinical Medicine, vol. 10, no. 23, Dec. 2021, p. 5676. PubMed Central, https://doi.org/10.3390/jcm10235676.
Tsui, Hing Wo, et al. “Association of a TNAP Haplotype with Ankylosing Spondylitis.” Arthritis and Rheumatism, vol. 56, no. 1, Jan. 2007, pp. 234–43. PubMed, https://doi.org/10.1002/art.22307.
VCV000013662.66 – ClinVar – NCBI. https://www.ncbi.nlm.nih.gov/clinvar/variation/13662/? Accessed 29 July 2026.
VCV000013684.25 – ClinVar – NCBI. https://www.ncbi.nlm.nih.gov/clinvar/variation/13684/? Accessed 29 July 2026.
VCV000551666.6 – ClinVar – NCBI. https://www.ncbi.nlm.nih.gov/clinvar/variation/551666/. Accessed 29 July 2026.
VCV001327158.6 – ClinVar – NCBI. https://www.ncbi.nlm.nih.gov/clinvar/variation/1327158/. Accessed 29 July 2026.
Whyte, Michael P., Katherine L. Madson, et al. “Asfotase Alfa Therapy for Children with Hypophosphatasia.” JCI Insight, vol. 1, no. 9, p. e85971. PubMed Central, https://doi.org/10.1172/jci.insight.85971. Accessed 29 July 2026.
Whyte, Michael P., Fan Zhang, et al. “Hypophosphatasia: Vitamin B6 Status of Affected Children and Adults.” Bone, vol. 154, Jan. 2022, p. 116204. PubMed, https://doi.org/10.1016/j.bone.2021.116204.
Wiedemann, Philip, et al. “Zinc and Vitamin D Deficiency and Supplementation in Hypophosphatasia Patients – A Retrospective Study.” Bone, vol. 175, Oct. 2023, p. 116849. PubMed, https://doi.org/10.1016/j.bone.2023.116849.
Zervou, Zografia, et al. “Hypophosphatasia and Neuropathic Pain: Related to Vitamin B6 Metabolism?” JBMR Plus, vol. 9, no. 8, Aug. 2025, p. ziaf086. PubMed, https://doi.org/10.1093/jbmrpl/ziaf086.

About the Author:
Debbie Moon is a biologist, engineer, author, and the founder of Genetic Lifehacks where she has helped thousands of members understand how to apply genetics to their diet, lifestyle, and health decisions. With more than 10 years of experience translating complex genetic research into practical health strategies, Debbie holds a BS in engineering from Colorado School of Mines and an MSc in biological sciences from Clemson University. She combines an engineering mindset with a biological systems approach to explain how genetic differences impact your optimal health.